August 28, 2011 – Utrecht, The Netherlands
Crossbeta Biosciences, a biotechnology company focused on the discovery and development of drug treatments for misfolded protein diseases, announced today that it has received a Grant of Eur 0.75 million for its lead program in Alzheimer’s Disease. The Grant was awarded by EuroTrans-Bio and allows Crossbeta Biosciences to progress the development of its disease-modifying treatment for Alzheimer’s Disease. This program specifically targets amyloid-b oligomers, the small protein aggregates that cause toxicity and inflammation in the brain of Alzheimer’s Disease patients.
Crossbeta Biosciences’ technology enables to study and specifically target protein species that cause or aggravate misfolded protein diseases such as Alzheimer’s Disease. Targeting these disease-specific misfolded proteins and inhibiting their negative effects creates novel treatment possibilities for these diseases.
Guus Scheefhals, CEO of Crossbeta Biosciences, said: “We are pleased with this recognition and financial support from EuroTrans-Bio for our Alzheimer’s Disease program and proud of the high ranking that our project obtained. This grant further strengthens our motivation to find a cure for this highly debilitating disease.”